1 week ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates Zacks
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of 1,400% and 273.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
X